Sirtex Medical: Biotech Market Spotlight

By Tim Dean
Friday, 23 October, 2009

Oncology treatment company, Sirtex Medical (ASX:SRX) has continued to perform well, gaining 23c or 3.85% today as of 3pm to $6.20.

This follows a week of strong gains following an announcement on Monday of a 68% increase in operating profit from $3.25 million to $5.47 million for the last financial quarter.

The company also announced a dividend of 2c per share plus a special dividend of 5c per share to be paid in December.

Sirtex Medical, which manufactures SIR-Spheres for the treatment of liver cancer, saw revenues raise from $12.29 million to $16.47 million in the last quarter, a lift of 34%, in spite of a strengthening Australian dollar.

The company's stock has performed well over since the start of the year, with it seeing a 280% lift since January 2.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd